COVID-19 vaccination provides additional protection against severe COVID-19-associated illness and death. Since September 2023, 2023-2024 Formula monovalent XBB.1-strain COVID-19 vaccines have been recommended for use in the United States for all persons aged ≥6 months. However, SARS-CoV-2 continues to evolve, and since winter 2023-2024, Omicron JN.1 lineage strains of SARS-CoV-2, including the JN.1 strain and the KP.2 strain, have been widely circulating in the United States. Further, COVID-19 vaccine effectiveness is known to wane. On June 27, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended 2024-2025 COVID-19 vaccination with a Food and Drug Administration (FDA)-approved or authorized vaccine for all persons aged ≥6 months. On August 22, 2024, FDA approved the 2024-2025 COVID-19 vaccines by Moderna and Pfizer-BioNTech (based on the KP.2 strain) for use in persons aged ≥12 years and authorized these vaccines for use in children aged 6 months-11 years under Emergency Use Authorization (EUA). On August 30, 2024, FDA authorized 2024-2025 COVID-19 vaccine by Novavax (based on the JN.1 strain) for use in persons aged ≥12 years under EUA. ACIP will continue to evaluate new evidence as it becomes available and will update recommendations as needed.

中文翻译：

---

6 个月以上人群使用 COVID-19 疫苗：免疫实践咨询委员会的建议 - 美国，2024-2025 年。


COVID-19 疫苗接种可针对与 COVID-19 相关的严重疾病和死亡提供额外保护。自 2023 年 9 月起，2023-2024 年单价 XBB.1 株 COVID-19 疫苗已被推荐在美国用于所有年龄≥6 个月的人群。然而，SARS-CoV-2 仍在不断进化，自 2023-2024 年冬季以来，SARS-CoV-2 的 Omicron JN.1 谱系毒株，包括 JN.1 毒株和 KP.2 毒株，已在全球广泛传播。美国。此外，已知 COVID-19 疫苗的有效性会减弱。 2024 年 6 月 27 日，免疫实践咨询委员会 (ACIP) 建议所有年龄 ≥ 6 个月的人使用食品和药物管理局 (FDA) 批准或授权的疫苗接种 2024-2025 年 COVID-19 疫苗。 2024年8月22日，FDA批准Moderna和辉瑞-BioNTech生产的2024-2025年COVID-19疫苗（基于KP.2毒株）用于12岁以上人群，并授权这些疫苗用于6个月大的儿童根据紧急使用授权 (EUA)，-11 年。 2024 年 8 月 30 日，FDA 批准 Novavax 的 2024-2025 年 COVID-19 疫苗（基于 JN.1 毒株）用于 EUA 下年龄≥12 岁的人群。 ACIP 将继续评估可用的新证据，并根据需要更新建议。